Company Plasmatech Biopharmaceuticals Inc Nasdaq
Stocks
US72754H1095
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 06-29 | Abeona Therapeutics Inc.(NasdaqCM:ABEO) dropped from Russell 3000E Growth Benchmark | CI |
| 06-29 | Abeona Therapeutics Inc.(NasdaqCM:ABEO) added to Russell 2000 Value-Defensive Index | CI |
Business description: Plasmatech Biopharmaceuticals Inc
Sales by Activity: Plasmatech Biopharmaceuticals Inc
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology (Startups) | 3M | 1.41M | 3.5M | - | 5.82M |
Geographical breakdown of sales: Plasmatech Biopharmaceuticals Inc
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 3M | 1.41M | 3.5M | - | 5.82M |
Executive Committee: Plasmatech Biopharmaceuticals Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Vishwas Seshadri
CEO | Chief Executive Officer | 50 | 14/10/2021 |
Joseph Vazzano
DFI | Director of Finance/CFO | 42 | 13/03/2022 |
James A. Gow
CTO | Chief Tech/Sci/R&D Officer | - | 19/10/2025 |
Brian Kevany
CTO | Chief Tech/Sci/R&D Officer | - | 31/05/2021 |
Greg Gin
IRC | Investor Relations Contact | - | 30/04/2020 |
Composition of the Board of Directors: Plasmatech Biopharmaceuticals Inc
| Director | Title | Age | Since |
|---|---|---|---|
Mark Alvino
BRD | Director/Board Member | 58 | 28/02/2006 |
Faith Charles
BRD | Director/Board Member | 64 | 24/03/2021 |
Leila Alland
BRD | Director/Board Member | 63 | 18/04/2021 |
Donald Wuchterl
BRD | Director/Board Member | 56 | 18/04/2021 |
Vishwas Seshadri
BRD | Director/Board Member | 50 | 14/10/2021 |
Bernhardt Zeiher
BRD | Director/Board Member | 62 | 07/08/2024 |
Eric Crombez
BRD | Director/Board Member | 53 | 11/08/2024 |
Keith Goldan
BRD | Director/Board Member | 55 | 31/03/2026 |
Company details: Plasmatech Biopharmaceuticals Inc
Abeona Therapeutics, Inc.
6555 Carnegie Avenue
44103, Cleveland
+646 813 4701
http://www.abeonatherapeutics.com
Biopharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.24% | +14.56% | +33.73% | -0.93% | 76.15B | |
| -0.67% | -9.93% | +19.90% | +179.40% | 48.89B | |
| -4.18% | +42.30% | +42.30% | +42.30% | 47.83B | |
| +1.01% | +8.83% | -52.93% | -53.63% | 41.37B | |
| -0.95% | +1.31% | +53.37% | -24.27% | 29.99B | |
| -0.49% | +0.60% | +53.23% | +84.03% | 24.23B | |
| +2.03% | +1.83% | +104.96% | -48.48% | 21.89B | |
| -0.81% | -4.39% | -7.53% | +165.02% | 19.25B | |
| -7.35% | -6.03% | +61.60% | +113.10% | 17.14B | |
| Average | -0.97% | +1.01% | +34.29% | +50.73% | 36.3B | |
| Weighted average by Cap. | -0.79% | +2.36% | +28.99% | +42.44% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- ABEO Stock
- Stock
- Company Plasmatech Biopharmaceuticals Inc
Select your edition
All financial news and data tailored to specific country editions
